The CURE Epilepsy Catalyst Award (2 years / $250,000) supports nimble development of data necessary to advance ideas toward larger commercialization funding opportunities and is not intended to replace those opportunities.
The purpose of this funding opportunity is to stimulate and accelerate discovery and development of new, transformative therapies for epilepsy, moving promising, well-supported preclinical and/or clinical research closer to clinical application. The award is intended to support nimble development of data necessary to attract larger commercialization funding opportunities and is not intended to replace those opportunities. Projects based on novel biological pathways and/or highly differentiated therapeutic approaches which are likely to have a high probability of successfully transitioning to clinical development are strongly encouraged. The award is not intended to fund basic research on the mechanisms underlying epilepsy.
Deadlines for Letter of Intent: June 10, 2025
This award is available to independent researchers at or above the level of Assistant Professor (or equivalent) at universities and non-academic research institutions, including small biotechnology companies, that seek to develop new interventions for epilepsy. International applicants are welcome to apply. Postdoctoral fellows may not apply for this award. All materials must be submitted in English.
Requests may be made for up to a total of $250,000 paid over 2 years. Funding requests may include salary support for the PI, technical staff and/or collaborators, supplies, animal costs, etc., and travel to an epilepsy-related conference if the PI is presenting his/her CURE Epilepsy-funded research. Limited equipment purchases that are required to complete goals will be considered. Indirect costs are not supported.